CorMedix Inc. (CRMD) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

CorMedix Inc. (CRMD)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

11.22

0.10 (0.90%)

At close: Jan 14, 2025, 3:59 PM

11.40

1.60%

Pre-market Jan 15, 2025, 05:37 AM EST

undefined% (undefined)

Bid	10.99
Market Cap	680.80M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.8
PE Ratio (ttm)	-14.02
Forward PE	n/a
Analyst	Buy

Ask	11.5
Volume	753,639
Avg. Volume (20D)	1,253,977
Open	11.24
Previous Close	11.12
Day's Range	10.98 - 11.42
52-Week Range	2.89 - 13.85
Beta	undefined

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical setting...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 13, 2010

Employees 82

Stock Exchange NASDAQ

Ticker Symbol CRMD

Website https://www.cormedix.com

Analyst Forecast

According to 6 analyst ratings, the average rating for CRMD stock is "Buy." The 12-month stock price forecast is $16, which is an increase of 42.60% from the latest price.

Buy 100.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

CorMedix Inc. is scheduled to release its earnings on Mar 11, 2025, before market opens.
Analysts project revenue of $19.79M, reflecting a n/a YoY growth and earnings per share of 0.05, making a -119.23% decrease YoY.

Why Price Moved

1 week ago · Source

+29.89%

CorMedix shares are trading higher after the compa... Unlock content with Pro Subscription

3 weeks ago · Source

+9.24%

CoreMedix shares are trading higher after the company announced it will be added to the Nasdaq Biotechnology Index.

News

6 days ago · zacks.com

CorMedix Stock Rises on Q4 Preliminary Sales Beating Estimates

CRMD reports $31 million in preliminary sales from its sole marketed product in Q4, surpassing its previous guidance of breaking even by 2024.

2 weeks ago · zacks.com

Is CorMedix (CRMD) Stock Outpacing Its Medical Peers This Year?

Here is how CorMedix (CRMD) and ResMed (RMD) have performed compared to their sector so far this year.

2 months ago · zacks.com

CorMedix (CRMD) Upgraded to Strong Buy: What Does It Mean for the Stock?

CorMedix (CRMD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

2 months ago · zacks.com

Best Momentum Stocks to Buy for November 8th

CRMD, FFIC and SPPJY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 8, 2024.

2 months ago · seekingalpha.com

Stock Picks From Seeking Alpha's October 2024 New Analysts

In October, 42 new analysts joined Seeking Alpha, sharing diverse investment ideas and strategies, from biotech to real estate. Highlighted strong buy recommendations include MicroStrategy, CorMedix, ...

2 months ago · zacks.com

New Strong Buy Stocks for November 8th

SPPJY, FFIC, CRMD, NTGR and AACAY have been added to the Zacks Rank #1 (Strong Buy) List on November 8, 2024.

2 months ago · zacks.com

Wall Street Analysts See a 52.15% Upside in CorMedix (CRMD): Can the Stock Really Move This High?

The consensus price target hints at a 52.2% upside potential for CorMedix (CRMD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

2 months ago · seekingalpha.com

CorMedix Inc. (CRMD) Q3 2024 Earnings Call Transcript

CorMedix Inc. (NASDAQ:CRMD ) Q3 2024 Earnings Call October 30, 2024 8:30 AM ET Company Participants Dan Ferry - Investor Relations Joe Todisco - Chief Executive Officer Matt David - Executive Vice Pre...

2 months ago · zacks.com

CorMedix (CRMD) Reports Q3 Loss, Tops Revenue Estimates

CorMedix (CRMD) came out with a quarterly loss of $0.05 per share versus the Zacks Consensus Estimate of a loss of $0.10. This compares to loss of $0.17 per share a year ago.

2 months ago · seekingalpha.com

CorMedix 2.0: New Leadership, New Approval, New Focus

CorMedix is a biopharmaceutical company that has undergone a re-birth as it enters a new phase with FDA approval of its anti-infective catheter solution, DefenCath. The company has faced challenges in...

2 months ago · seekingalpha.com

Undercovered Dozen: CorMedix, Cabaletta, Skyx Platforms, Dynex Capital +

The 'Undercovered' Dozen highlights 12 lesser-covered stock ideas from October 18th - 24th, offering fresh investment takes for community discussion. Dnis Buivolov updates their Nebius Group valuation...